“Erectile Dysfunction – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global Erectile Dysfunction (ED) therapeutics market. The report identifies the key trends shaping and driving the ED market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ED therapeutics sector. GlobalData’s analysis revealed that the market grew at a CAGR of 9.8% from 2001 to 2009. The growth rate was moderate due lack of ED awareness and reluctance among male general population to discuss their sexual problem. With the patent expiry of a key product, Viagra, in 2012, the market is expected to decline after 2011, resulting in a CAGR of 4% from 2009 to 2016.

GlobalDatas analysis showed that the ED pipeline is weak. The products in the ED pipeline comprises of me-too class. Some of the promising me-too class drugs/molecules are likely to get approval in coming years which are in phase III trials. One of the promising molecule include Avanafil , which is unlikely to have much impact as market has high competition among similar products and generic erosion after 2012 due to patent expiry of Viagra (sildenafil citrate).

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global ED therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include FKBP12 binder, serotonin and dopamine enhancer, PDE-5 inhibitor, and Alpha1A-adrenoreceptors antagonist.
- Analysis of the current and future market competition in the global ED therapeutics market. Key market players covered are VIVUS, Inc., and Rexahn Pharmaceuticals, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with ED.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global erectile dysfunction market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global erectile dysfunction market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global erectile dysfunction market landscape? – Identify, understand and capitalize.

Companies Mentioned

VIVUS, Inc
Rexahn Pharmaceuticals, Inc

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3099/Erectile-Dysfunction-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical report offering, “Herpes Simplex – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global herpes simplex market. The report identifies the key trends shaping and driving the global herpes simplex market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global herpes simplex therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

GlobalData finds that the global herpes simplex market was worth approximately $2.9 billion in 2009. The global herpes simplex therapeutics market is expected to grow at a CAGR of 11.1% between 2009 and 2016. The primary factor contributing to the increase in revenues over the forecast period is the increase in disease incidence. Presently the therapeutic regimen for Herpes Simplex is dominated by a range of DNA polymerase inhibitors which include Zovirax, Famvir, Valtrex, Denavir and OTC products such as Abreva and Aviralex. This market is a significantly genericized market with many brands across the major seven geographies.

Scope

- Annualized global herpes simplex market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Key geographies covered in this report include the US (United States), the UK (united Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include DNA polymerase inhibitors, Helicase-primase inhibitors, NFkB regulators, HSV-2 gene and nectin-1 receptor targetters, viral maturation inhibitors and PDI inhibitors.
- Analysis of the current and future market competition in the global herpes simplex market. Key market players covered are BioAlliance Pharma, Nutra Pharma Corporation and AiCuris GmbH & Co. KG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with herpes simplex therapeutics.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global herpes simplex market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global herpes simplex market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global herpes simplex market landscape? – Identify, understand and capitalize.

Companies Mentioned

Bioalliance Pharma
Nutra Pharma Corporation
AiCuris GmbH and Co. KG

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3141/Herpes-Simplex-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical report offering, “Anemia – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global anemia market. The report identifies the key trends shaping and driving the global anemia market. The report also provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global anemia market. GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a Compound Annula Growth Rate (CAGR) of 8.5% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. GlobalData evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. However, the majority of the ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global anemia market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, transforming growth factor (TGF)-beta inhibitors and transferrin receptor (TfR) targetters.
- Analysis of the current and future market competition in the global anemia market. Key future market players covered are Affymax, Pharmacosmos, Amgen Inc., Hoffmann-La Roche, Chugai – Pharmaceutical Celgene Corporation, Hoffmann-La Roche, and Johnson and Johnson.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the anemia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global anemia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global anemia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global anemia market landscape? – Identify, understand and capitalize.

Companies Mentioned

Affymax
Pharmacosmos
Amgen Inc
Celgene Corporation
Chugai Pharmaceutical
Hoffmann-La Roche
Johnson & Johnson

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3140/Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Energy report “South and Central American National Oil Companies (NOC) – Focused Investments and Rapid Upstream Developments Transforming the Region” analyzes the role of South and Central American National Oil Companies (NOCs) globally. The report analyzes the upstream oil and gas sector in South and Central America in terms of reserves and production growth, the number of discoveries and key growth areas. The report details the importance of the South and Central American NOCs in the domestic upstream sector and also provides production forecasts for all important NOCs in the region to 2020. The report also details the investment plans of all these NOCs. It discuses the role of these NOCs in the midstream and downstream sectors as well and providing the key planned projects by sector. The report also provides details of the major joint ventures and partnerships entered into by these NOCs over the past few years with foreign companies to develop their domestic oil and gas industries.

Scope

The report analyzes market opportunities and challenges for the global The South and Central America National Oil Companies (NOC). The scope of the report includes:
- The upstream sector in South and Central America with reserves growth, production trends during 2000-2009, discoveries in the region and major prolific areas for future growth.
- Analysis of the major NOCs in the region, namely PDVSA, Pertrobras, Pemex, Ecopetrol and Petroecuador, in terms of activities in the domestic upstream sector, and also provides oil and gas production forecasts for the companies until 2020. key countries covered include Brazil, Venezuela and Colombia
- The role of these NOCs in the midstream and downstream sectors detailing the planned projects by the NOCs in these sectors.
- Information on the global operations of the South and Central American NOCs detailing core operational areas.
- Details of major joint venture/partnerships entered into by South and Central American NOCs for developing their domestic oil and gas industries.
- Discussion on the growing role of South and Central American NOCs in the oil and gas industry of the region to 2020 and its impact on the global market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies with the help of specific insights about the South and Central American oil and gas market.
- Benchmark your operations against the operations and strategies adopted by these major National Oil Companies.
- Identify opportunities to partner with these fast growing National Oil Companies.
- Understand the working and strategies of the South and Central American NOCs and decide your future strategies accordingly.
- Identify the key regions of growth in South and Central America to expand your business in this lucrative region.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3139/South-and-Central-America-National-Oil-Companies-NOC-Focused-Investments-and-Rapid-Upstream-Developments-Transforming-the-Region.html
———————————————-

Medical equipment offering, “South Africa Diabetes Care Devices Market Outlook to 2016” provides key market data on the South Africa diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for two diabetes care devices market categories – Glucose Monitoring and Insulin Delivery.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories.
• Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the two market categories.
• Global corporate-level profiles of key companies operating within the South Africa diabetes care devices market. Key players covered include F. Hoffmann-La Roche Ltd., LifeScan, Inc., Bayer HealthCare AG, Abbott Laboratories, Medtronic, Inc., Becton, Dickinson and Company and Novo Nordisk A/S.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the South Africa diabetes care devices competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Bayer HealthCare AG
LifeScan, Inc.
Sanofi-Aventis
Novo Nordisk A/S
Eli Lilly and Company
B. Braun Melsungen AG
Medtronic, Inc.
Abbott Laboratories
Becton, Dickinson and Company
Smiths Medical
Terumo Corporation
ARKRAY, Inc.
Apex Biotechnology Corp.
Animas Corporation

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3198/South-Africa-Diabetes-Care-Devices-Market-Outlook-to-2016.html
———————————————-

Medical equipment offering, “Mexico Diabetes Care Devices Market Outlook to 2016” provides key market data on the Mexico diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for two diabetes care devices market categories – Glucose Monitoring and Insulin Delivery.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories.
• Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the two market categories.
• Global corporate-level profiles of key companies operating within the Mexico diabetes care devices market. Key players covered include F. Hoffmann-La Roche Ltd., LifeScan, Inc., Bayer HealthCare AG, Abbott Laboratories, Medtronic, Inc., Becton, Dickinson and Company and Novo Nordisk A/S.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Mexico diabetes care devices competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

F. Hoffmann-La Roche Ltd.
LifeScan, Inc.
Bayer HealthCare AG
Abbott Laboratories
B. Braun Melsungen AG
Novo Nordisk A/S
Sanofi-Aventis
Medtronic, Inc.
Eli Lilly and Company
Becton, Dickinson and Company
Smiths Medical
Terumo Corporation
ARKRAY, Inc.
Apex Biotechnology Corp.
Animas Corporation

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3197/Mexico-Diabetes-Care-Devices-Market-Outlook-to-2016.html
———————————————-

Medical equipment offering, “Belgium Diabetes Care Devices Market Outlook to 2016” provides key market data on the Belgium diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for two diabetes care devices market categories – Glucose Monitoring and Insulin Delivery.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories.
• Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the two market categories.
• Global corporate-level profiles of key companies operating within the Belgium diabetes care devices market. Key players covered include F. Hoffmann-La Roche Ltd., LifeScan, Inc., Bayer HealthCare AG, Abbott Laboratories, Medtronic, Inc., Becton, Dickinson and Company and Novo Nordisk A/S.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Belgium diabetes care devices competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
LifeScan, Inc.
Bayer HealthCare AG
Eli Lilly and Company
Medtronic, Inc.
Novo Nordisk A/S
B. Braun Melsungen AG
Abbott Laboratories
Becton, Dickinson and Company
Smiths Medical
Terumo Corporation
ARKRAY, Inc.
Apex Biotechnology Corp.
Animas Corporation

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3196/Belgium-Diabetes-Care-Devices-Market-Outlook-to-2016.html
———————————————-

Medical equipment offering, “Netherlands Diabetes Care Devices Market Outlook to 2016” provides key market data on the Netherlands diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for two diabetes care devices market categories – Glucose Monitoring and Insulin Delivery.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories.
• Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the two market categories.
• Global corporate-level profiles of key companies operating within the Netherlands diabetes care devices market. Key players covered include F. Hoffmann-La Roche Ltd., LifeScan, Inc., Bayer HealthCare AG, Abbott Laboratories, Medtronic, Inc., Becton, Dickinson and Company and Novo Nordisk A/S.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Netherlands diabetes care devices competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
Bayer HealthCare AG
Abbott Laboratories
LifeScan, Inc.
Eli Lilly and Company
Medtronic, Inc.
Novo Nordisk A/S
Becton, Dickinson and Company
Smiths Medical
B. Braun Melsungen AG
Terumo Corporation
ARKRAY, Inc.
Apex Biotechnology Corp.
Animas Corporation
Diabetes Management International BV

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3195/Netherlands-Diabetes-Care-Devices-Market-Outlook-to-2016.html
———————————————-

Medical equipment offering, “Brazil Diabetes Care Devices Market Outlook to 2016” provides key market data on the Brazil diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for two diabetes care devices market categories – Glucose Monitoring and Insulin Delivery.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories.
• Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the two market categories.
• Global corporate-level profiles of key companies operating within the Brazil diabetes care devices market. Key players covered include F. Hoffmann-La Roche Ltd., LifeScan, Inc., Bayer HealthCare AG, Abbott Laboratories, Medtronic, Inc., Becton, Dickinson and Company and Novo Nordisk A/S.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Brazil diabetes care devices competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

F. Hoffmann-La Roche Ltd.
LifeScan, Inc.
Novo Nordisk A/S
Sanofi-Aventis
Medtronic, Inc.
Bayer HealthCare AG
Becton, Dickinson and Company
B. Braun Melsungen AG
Abbott Laboratories
Smiths Medical
Terumo Corporation
ARKRAY, Inc.
Apex Biotechnology Corp.
Animas Corporation
Eli Lilly and Company

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3194/Brazil-Diabetes-Care-Devices-Market-Outlook-to-2016.html
———————————————-

Medical equipment offering, “Australia Diabetes Care Devices Market Outlook to 2016” provides key market data on the Australia diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for two diabetes care devices market categories – Glucose Monitoring and Insulin Delivery.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories.
• Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the two market categories.
• Global corporate-level profiles of key companies operating within the Australia diabetes care devices market. Key players covered include F. Hoffmann-La Roche Ltd., LifeScan, Inc., Bayer HealthCare AG, Abbott Laboratories, Medtronic, Inc., Becton, Dickinson and Company and Novo Nordisk A/S.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Australia diabetes care devices competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

Novo Nordisk A/S
F. Hoffmann-La Roche Ltd.
LifeScan, Inc.
Sanofi-Aventis
Medtronic, Inc.
Eli Lilly and Company
Bayer HealthCare AG
B. Braun Melsungen AG
Abbott Laboratories
Becton, Dickinson and Company
Smiths Medical
Terumo Corporation
ARKRAY, Inc.
Apex Biotechnology Corp.
Animas Corporation
AiMedics Pty Ltd
Roche Diagnostics Australia Pty. Ltd.
National Diagnostics Products Pty. Limited

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3193/Australia-Diabetes-Care-Devices-Market-Outlook-to-2016.html
———————————————-